Author

X. Huang

Institutions: Fujian Women and Children Hospital, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)

Observed institutions: Fujian Women and Children Hospital, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)

OpenAlex ID: A5030344992

S218: a Phase I/ii Study of Golidocitinib, a Selective Jak1 Inhibitor, in Refractory or Relapsed Peripheral T Cell Lymphoma

2022 · W.-S. Kim, D.-H. Yoon, et al. · HemaSphere · 1

Impact of biomarkers and other diseases on breast cancer risk and mortality: prospective cohort study in the UK Biobank

2022 · Y. Zhang, Y. Lin, et al. · European Journal of Cancer

425P Novel CoupledCAR technology for treating colorectal cancer

2022 · J. Cui, N. Chen, et al. · Annals of Oncology

Works count: 3

Citation count: 1

H-index: 1

I10-index: